Medics should plan ahead for incidental findings
By Erika Check Hayden,
Nature News
| 12. 12. 2013
Doctors, researchers and companies should expect to find information they were not looking for in genetic analyses, imaging scans and other tests, concludes a report from the US Presidential Commission for the Study of Bioethical Issues. Moreover, medics and investigators should discuss with patients and research volunteers how these potentially serious findings will be handled before the tests are carried out.
The advice given by the report echoes previous recommendations in specific fields. Still, researchers say it is a useful summary of basic overarching principles for grappling with 'incidental findings' that occur when a test ordered for one purpose uncovers information about another, unrelated health risk.
“They get to the heart of what needs to be done, and there is a need to codify this,” says James Evans, a geneticist at the University of North Carolina in Chapel Hill, of the panel's recommendations.
Although incidental findings have always occurred in medicine and research, the rise of more omniscient tests that can reveal large amounts of information about a person’s risk factors have posed urgent ethical questions about how to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...